Executive Interviews

  1. Increasing Diversity Among Leadership And Boards
    7/1/2019

    Biopharmaceutical executives Ron Cohen, Acorda Therapeutics; John Maraganore, Alnylam; and Helen Torley, Halozyme Therapeutics, discuss BIO’s approach toward increasing diversity among the industry’s leadership.

  2. Ending Generic Drug Shortages At Hospitals: A Capitalist Goes Nonprofit
    7/1/2019

    The nonprofit CivicaRX continues to gain momentum, and the company’s president and CEO, Martin Van Trieste, believes it’s a business model that is “pro-competition,” and one that others throughout the biopharma industry can adapt as well.

  3. Bassil Dahiyat’s Two-Decade Biotech Startup Odyssey
    7/1/2019

    Xencor’s story seems riddled with more than your average share of challenges, hurdles, and outright roadblocks. But it’s the outcome of that story — a growing company now valued at roughly $1.8 billion with nine drugs in the clinic and 150 employees — that truly make’s Xencor’s journey so compelling.

  4. Developing Cannabinoid Pharmaceuticals Amid The “Cannabusiness” Craze
    5/31/2019

    A lot of Big Pharma companies were on the sidelines because they were unclear how cannabinoid therapeutics would be regulated by the FDA,” explains Alex Wasyl, CEO of Nexien BioPharma.

  5. Should Pharma Care About Digital Therapeutics?
    5/31/2019

    So, why should pharma care about digital therapeutics? This was just one of the questions posed to a panel of digital therapeutics experts during the 2018 CNS Summit.

  6. The Whirlwind Rise Of Orchard Therapeutics
    5/31/2019

    While some might think Orchard’s whirlwind rise to be a bit of luck and good timing, the reality is it involved an extremely well-executed plan — and maybe a small dose of good fortune.

  7. GlycoMimetics Aiming At Tough Targets
    5/1/2019

    An exclusive interview with Rachel King, a business person dedicated to a science-driven sector, who is CEO of GlycoMimetics, an oncology-focused biotechnology company.

  8. Regeneron Manages Clinical Costs In A Fast-Growing Organization
    5/1/2019

    Bari Kowal, VP and head of global clinical operations at Regeneron, says sponsors and CROs must partner to make clinical trial execution more efficient and cost-effective.

  9. The Impact Of A Biotech CEO On Company Growth
    5/1/2019

    An inside look at how CEO Yuval Cohen communicates and interacts with employees at Corbus Pharmaceuticals, and how all of that affects the company’s culture.

  10. Medicines360 On A Mission For Women
    5/1/2019

    Medicines360 is using all its developed-world revenue to extend access to essential medicines to all women, regardless of the economic and healthcare circumstances in their part of the world.